- |||||||||| lexatumumab (ETR2-ST01) / GSK
Journal: Celastrol enhances TRAIL?R2?mediated apoptosis and cytotoxicity in human renal cell carcinoma cells in caspase?dependent manner. (Pubmed Central) - Nov 28, 2023
Furthermore, the cytotoxicity induced by that combination was significantly suppressed by the DR5:Fc chimeric protein, as well as specific inhibitors of caspase?8, ?9, ?6 and ?3. Taken together, these results indicated that celastrol enhances both TRAIL?R2?mediated apoptosis and cytotoxicity by upregulating TRAIL?R2 and activating the caspase cascade, indicating the possibility of using it in combination with lexatumumab as an innovative therapeutic strategy for treating RCC.
- |||||||||| mapatumumab (HGS-ETR1) / GSK, lexatumumab (ETR2-ST01) / GSK
Review, Journal: TRAIL-mediated signaling in bladder cancer: realization of clinical efficacy of TRAIL-based therapeutics in medical oncology. (Pubmed Central) - Jul 15, 2023
Certain clues of scientific evidence have provided encouraging results about efficacy of these agonistic antibodies (lexatumumab and mapatumumab) against bladder cancer cell lines. Therefore, multipronged approaches consisting of natural products, chemotherapeutics, and agonistic antibodies will realistically and mechanistically provide proof-of-concept for the translational potential of these combinatorial strategies in well-designed clinical trials.
- |||||||||| mapatumumab (HGS-ETR1) / GSK, lexatumumab (ETR2-ST01) / GSK
Journal: miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cells. (Pubmed Central) - Feb 11, 2022
Our data further suggests that the binding of miR-3132 to toll-like receptors could be the upstream pathway for the interferon response. The current study the first report to demonstrate miR-3132's in vitro efficacy and preliminary mechanism of action in cancer cell lines.
- |||||||||| mapatumumab (HGS-ETR1) / GSK, lexatumumab (ETR2-ST01) / GSK
Journal, PARP Biomarker: Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells. (Pubmed Central) - Jan 4, 2020
In both cellular systems, we could clearly demonstrate the potentiating effects of p53 on TRAIL-R-mediated IL-8 induction. In conclusion, we found that wild-type p53 increases TRAIL-R-mediated apoptosis but simultaneously augments non-apoptotic signaling.
- |||||||||| lexatumumab (ETR2-ST01) / GSK
Enrollment change, IO biomarker: HGS-ETR2 to Treat Children With Solid Tumors (clinicaltrials.gov) - Apr 6, 2018
P1, N=30, Terminated,
In conclusion, we found that wild-type p53 increases TRAIL-R-mediated apoptosis but simultaneously augments non-apoptotic signaling. N=19 --> 30
- |||||||||| lexatumumab (ETR2-ST01) / GSK
Trial completion, IO biomarker: HGS-ETR2 to Treat Children With Solid Tumors (clinicaltrials.gov) - Oct 17, 2011
P1, N=19, Completed,
N=73 --> 19 Active, not recruiting --> Completed
|
